Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
61.66 USD | -0.08% | -4.88% | +11.82% |
May. 21 | Ani Pharmaceuticals Insider Sold Shares Worth $794,568, According to a Recent SEC Filing | MT |
May. 20 | ANI Pharmaceuticals Launches Kionex Suspension | MT |
Business Summary
Number of employees: 642
Sales per Business
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Generics, Established Brands, and Other
77.0
%
| 275 | 86.8 % | 375 | 77.0 % | +36.40% |
Rare Disease
23.0
%
| 42 | 13.2 % | 112 | 23.0 % | +168.95% |
Sales per region
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
United States
99.9
%
| 312 | 98.7 % | 486 | 99.9 % | +55.64% |
Canada
0.1
%
| 4 | 1.3 % | 1 | 0.1 % | -85.73% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Nikhil Lalwani
CEO | Chief Executive Officer | 46 | 20-09-07 |
Stephen Carey
DFI | Director of Finance/CFO | 53 | 16-05-05 |
Patrick Walsh
CHM | Chairman | 63 | 18-05-16 |
Elizabeth Powell
CMP | Compliance Officer | - | 22-02-23 |
Mary Pao
CTO | Chief Tech/Sci/R&D Officer | - | 22-02-23 |
Chief Tech/Sci/R&D Officer | 56 | 21-11-18 | |
James Marken
COO | Chief Operating Officer | 61 | 07-02-28 |
Krista Davis
HRO | Human Resources Officer | 51 | 22-09-11 |
Meredith Cook
LAW | General Counsel | 50 | 22-07-17 |
Ori Gutwerg
PRN | Corporate Officer/Principal | 50 | 21-01-31 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Thomas Haughey
BRD | Director/Board Member | 60 | 18-04-30 |
Antonio Pera
BRD | Director/Board Member | 66 | 20-08-05 |
David Nash
BRD | Director/Board Member | 68 | 18-09-30 |
Patrick Walsh
CHM | Chairman | 63 | 18-05-16 |
Renee Tannenbaum
BRD | Director/Board Member | 72 | 22-03-21 |
Jeanne A. Thoma
BRD | Director/Board Member | 64 | 20-08-05 |
Chief Tech/Sci/R&D Officer | 56 | 21-11-18 | |
Nikhil Lalwani
CEO | Chief Executive Officer | 46 | 20-09-07 |
Matthew Leonard
BRD | Director/Board Member | 58 | 23-08-20 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 0 | 10,864 | 0 | 0 | 80.56 % |
Stock B | 1 | 21,354,608 | 17,211,374 ( 80.60 %) | 392,959 ( 1.840 %) | |
Stock C | 0 | 25,000 | 0 | 0 |
Company contact information
ANI Pharmaceuticals, Inc.
210 Main Street West
56623, Baudette
+218 634 3500
http://www.anipharmaceuticals.comSector
Sales per Business
Sales per region
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+11.82% | 1.2B | |
+37.74% | 723B | |
+34.79% | 595B | |
-2.07% | 369B | |
+20.25% | 332B | |
+2.99% | 282B | |
+17.15% | 244B | |
+9.98% | 208B | |
-4.21% | 205B | |
+7.43% | 166B |
- Stock Market
- Equities
- ANIP Stock
- Company ANI Pharmaceuticals, Inc.